Mindfulness Based Relapse Prevention for Stimulant Users (MBRP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01094223|
Recruitment Status : Unknown
Verified December 2015 by Suzette Glasner-Edwards, University of California, Los Angeles.
Recruitment status was: Active, not recruiting
First Posted : March 26, 2010
Last Update Posted : December 18, 2015
|Condition or disease||Intervention/treatment||Phase|
|Stimulant Dependence||Behavioral: Mindfulness Based Relapse Prevention Behavioral: Health Education||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mindfulness Based Relapse Prevention for Stimulant Users|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||April 2012|
|Estimated Study Completion Date :||December 2015|
Behavioral: Mindfulness Based Relapse Prevention
Meditation based therapy group incorporating relapse prevention skills training
|Active Comparator: Health Education||
Behavioral: Health Education
Psychoeducation group focused on various topics pertaining to physical health
- Depressive symptoms [ Time Frame: baseline (week 0), weekly during treatment (weeks 1-12), and at follow-up (week 24) ]The Beck Depression Inventory (BDI), a well validated self-report measure (Beck, 1967) will be administered at baseline, weekly during treatment, and at follow-up. Both the absolute total scores and change scores will be used for analyses.
- HIV Risk behaviors [ Time Frame: baseline (week 0), treatment-end (week 12), and follow up (week 24) ]The HIV Risk Assessment Battery (Navaline et al., 1994) will be administered at baseline, treatment-end, and FU to assess the impact of the interventions on changes in HIV/AIDS-related risk behaviors.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01094223
|United States, California|
|Los Angeles, California, United States, 90025|
|Principal Investigator:||Suzette Glasner-Edwards, Ph.D.||University of California, Los Angeles|